Open AccessExpression of Integrin α v β 3 in Gliomas Correlates with Tumor Grade and Is not Restricted to Tumor Vasculature
Author(s) -
Schnell Oliver,
Krebs Bjarne,
Wagner Erika,
Romagna Alexander,
Beer Ambros J.,
Grau Stefan J.,
Thon Niklas,
Goetz Claudia,
Kretzschmar Hans A.,
Tonn JörgChristian,
Goldbrunner Roland H.
Publication year - 2008
Publication title -
brain pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.986
H-Index - 132
eISSN - 1750-3639
pISSN - 1015-6305
DOI - 10.1111/j.1750-3639.2008.00137.x
Subject(s) - integrin , cancer research , glioblastoma , glioma , pathology , medicine , biology , receptor
In malignant gliomas, the integrin adhesion receptors seem to play a key role for invasive growth and angiogenesis. However, there is still a controversy about the expression and the distribution of α v β 3 integrin caused by malignancy. The aim of our study was to assess the extent and pattern of α v β 3 integrin expression within primary glioblastomas (GBMs) compared with low‐grade gliomas (LGGs). Tumor samples were immunostained for the detection of α v β 3 integrin and quantified by an imaging software. The expression of α v β 3 was found to be significantly higher in GBMs than in LGGs, whereby focal strong reactivity was restricted to GBMs only. Subsequent analysis revealed that not only endothelial cells but also, to a large extent, glial tumor cells contribute to the overall amount of α v β 3 integrin in the tumors. To further analyze the integrin subunits, Western blots from histologic sections were performed, which demonstrated a significant difference in the expression of the β 3 integrin subunit between GBMs and LGGs. The presented data lead to new insights in the pattern of α v β 3 integrin in gliomas and are of relevance for the inhibition of α v β 3 integrin with specific RGD peptides and interfering drugs to reduce angiogenesis and tumor growth.